{"id":"W2143000374","doi":"10.1007/s00417-012-2123-4","title":"Balancing risk in ophthalmic prescribing: assessing the safety of anti-VEGF therapies and the risks associated with unlicensed medicines","year":2012,"lang":"en","type":"review","venue":"Graefe s Archive for Clinical and Experimental Ophthalmology","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Dalhousie University","funders":"Novartis Pharma","keywords":"Pegaptanib; Ranibizumab; Medicine; Bevacizumab; Macular degeneration; Intensive care medicine; Aflibercept; Clinical trial; European union; Ophthalmology; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009459258,0.0009490548,0.003098551,0.005082069,0.0002656499,0.002203615,0.0009689254,0.002264441,0.002397395],"category_scores_gemma":[0.02702521,0.0004438723,0.002030059,0.005867152,0.0007774011,0.002201668,0.0008456777,0.001296885,0.0002774267],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002381969,"about_ca_system_score_gemma":0.004382709,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00392705,"about_ca_topic_score_gemma":0.00534772,"domain_scores_codex":[0.9938287,0.003993241,0.0006012311,0.0001838506,0.00127395,0.0001189679],"domain_scores_gemma":[0.9773244,0.01845128,0.002795252,0.0001659741,0.001151373,0.0001117076],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002278443,0.0001107008,0.002588307,0.04585749,0.001767363,0.0002065457,0.0001511849,0.002470164,0.0001474337,0.01068638,0.006402334,0.9293842],"study_design_scores_gemma":[0.0009111139,0.001639887,0.0568299,0.3040155,0.01583537,0.006321046,0.002494859,0.0122178,0.002268871,0.0948474,0.5021513,0.0004670039],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000897895,0.9962689,0.0005341921,0.0009935478,0.00005287657,0.00002177407,0.00002831,0.000002883929,0.001199637],"genre_scores_gemma":[0.01709236,0.9812421,0.001016507,0.0002586308,0.000145795,0.00003494084,0.00003672561,0.000002635883,0.0001702628],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.009459258,"threshold_uncertainty_score":0.05002594,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.5342640919627406,"score_gpt":0.5376408697069376,"score_spread":0.003376777744196979,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}